United States· US:83296-100_26bdd232-8068-9080-e063-6394a90aa084
XOLREMDI
A mavorixafor product containing mavorixafor, registered in United States by X4 Pharmaceuticals, Inc.. The same ATC class is registered in 7 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Mavorixafor is registered in 7 of 19 countries.
Countries holding a registration under ATC L03AX24 (mavorixafor), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 5 of them publish a price we can compare per daily dose
Mavorixafor · ATC L03AX24
7 / 19 countries
- Belgiumprice
- Czechiaprice
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- MAVORIXAFOR
- Manufacturer
- X4 Pharmaceuticals, Inc.
- Country
- United States (US)
- ATC code
- L03AX24
- ATC class
- Mavorixafor
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 6
- ndc1183296-100-12
- ndc1183296-100-60
- ndc1183296-100-90
- ndc118329610012120 CAPSULE, GELATIN COATED in 1 BOTTLE (83296-100-12)
- ndc11832961006060 CAPSULE, GELATIN COATED in 1 BOTTLE (83296-100-60)
- ndc11832961009090 CAPSULE, GELATIN COATED in 1 BOTTLE (83296-100-90)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mavorixafor in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaXOLREMDINorgine B.V., Amsterdam
- FinlandXolremdiNorgine B.V.
- IrelandXolremdi 100mg hard capsuleNorgine B.V.
- IcelandXolremdiNorgine B.V.
- NetherlandsXolremdi 100 mg harde capsuleNorgine B.V.
- PolandXolremdiX4 Pharmaceuticals (Austria) GmbH
- BelgiumXolremdi 100 mgNorgine
- SwedenXolremdi 100 mg Kapsel, hårdNorgine BV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Xolremdi
- Liechtenstein · Xolremdi
- Norway · Xolremdi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e7ef4c28-eca4-41ac-91ef-b71c990c1acd GET /v1/drugs/e7ef4c28-eca4-41ac-91ef-b71c990c1acd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "100",
"substance": "MAVORIXAFOR",
"productndc": "83296-100",
"dosage_form": "CAPSULE, GELATIN COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA218709",
"marketing_category": "NDA"
}See everything about mavorixafor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.